TEVA ▲ +2.3% - Teva Pharmaceutical Industries Limited $TEVA - Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Teva Pharmaceutical Industries rose 2.3% following announcement of positive topline results from a Phase 2a trial of its anti-IL-15 antibody for celiac disease treatment. The positive clinical data supports the company's pipeline strategy and demonstrates progress in expanding its therapeutic platform, which drove investor optimism in the stock. 02-SEP-2026 07:03 AM ET